Update of recent clinical trials in heart failure and myocardial infarction

European Journal of Heart Failure

Volumn 1, Issue 1, 2000, Pages 109-115

  Richardson, Mark ^a   Cockburn, Neil ^a   Cleland, John G F ^a,b  

^a Cardionet Editorial Office   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; Double blind; Heart failure; Myocardial infarction; Placebo controlled; Randomised

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CANDESARTAN; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAPRIL; INOTROPIC AGENT; LISINOPRIL; METOPROLOL; MIBEFRADIL; PIPERANOMETOZINE; SPIRONOLACTONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0033086862     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(99)00008-2     Document Type: Article

References (12)

1. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. J Am Med Assoc 1995;10:1450-1456.
2. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs 1996;51:89-98.
3. Pool PE. Neurohormonal activation in the treatment of congestive heart failure: Basis for new treatments? Cardiology 1998;90:1-7.
4. CIBIS II Scientific Committee. Design of the cardiac insufficiency bisoprolol study II. Fundam Clin Pharmacol 1997; 11:138-142.
5. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
6. The International Steering Committee. Rationale, design, and organisation of the metoprolol CR/XL randomised intervention trial in heart failure (MERIT-HF). Am J Cardiol 1997;80:54J-58J.
7. Tsuyuki RT, Yusuf S, Rouleau JL et al. Combined neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Can J Cardiol 1997;13:1166-1174.
8. Cohn JN, Goldstein SO, Greenberg BH et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;39:1810-1816.
9. Levine TB. The design of the mortality assessment in congestive heart failure trial (MACH-1, mibefradil). Clin Cardiol 1997;20:320-326.
10. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. The randomized aldactone evaluation study (RALES). Am J Cardiol 1996;78:902-907.
11. Siebels J, Cappato R, Ruppel R, Sneider MA, Kuck KH. Preliminary results of the cardiac arrest study Hamburg (CASH). CASH investigators. Am J Cardiol 1993;72:109F-113F.
12. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. New Engl J Med 1997;337:1569-1575.